Citations

Showing 10 of 108104 citations.

International external validation of a stratification tool to identify branch‐duct intraductal papillary mucinous neoplasms at lowest risk of progression
Overbeek, Kasper A. , Leeuwen, Nikki van , Tacelli, Matteo , Anwar, Muhammad , Yousaf, Muhammad Nadeem , Chhoda, Ankit , Arcidiacono, Paolo Giorgio , Gonda, Tamas A. , Wallace, Michael B. , Capurso, Gabriele , Farrell, James J. , Cahen, Djuna L. , Bruno, Marco J. , Arcidiacono, Paolo Giorgio , Wallace, Michael B , Tacelli, Matteo

Mayo Clinic

United European Gastroenterology Journal | February 24, 2022 | Volume: 10 | Issue: 2 | Pages: 169-178

10.1002/ueg2.12207 | PMID 35199484 Get It

AbstractBackgroundIdentifying branch‐duct intraductal papillary mucinous neoplasms (BD‐IPMNs) at lowest risk of progression may allow for a reduced intensity of surveillance.ObjectiveWe aimed to externally validate the previously developed Dutch‐American Risk stratification Tool (DART‐1; https://rtools.mayo.edu/DART/), which identifies cysts at low risk of developing worrisome features (WFs) or high‐risk stigmata (HRS).MethodsThree prospective cohorts of individuals under surveillance for BD‐IPMNs were combined, independent from the original development cohort. We assessed the performance (discrimination and calibration) of DART‐1, a multivariable Cox‐proportional logistic regression model with five predictors for the development of WFs or HRS.ResultsOf 832 individuals (mean age 77 years, SD 11.5) under surveillance for a median of 40 months (IQR 44), 163 (20%) developed WFs or HRS. DART‐1's discriminative ability (C‐statistic 0.68) was similar to that in the development cohort (0.64–0.72) and showed moderate calibration. DART‐1 adequately estimated the risk for patients in the middle risk quintile, and slightly underestimated it in the lowest quintiles. Their range of predicted versus observed 3‐year risk was 0%–0% versus 0%–3.7% for Q1; 0.3%–0.4% versus 3%–11% for Q2; and 2.6%–3% versus 2.4%–9.8% for Q3. The development of WFs or HRS was associated with pancreatic cancer (p < 0.001). Vice versa, in absence of WFs or HRS, the risk of malignancy was low (0.3%).ConclusionsThe performance of DART‐1 to predict the development of WFs or HRS in BD‐IPMN was validated in an external international cohort, with a discriminative ability equal as in the development cohort. Risk estimations were most accurate for patients with BD‐IPMNs in the middle risk quintile and slightly underestimated in the lowest quintiles.
Evaluating the impact of a social medicine course delivered in a local‐global context: A 10‐year multi‐site analysis
Voller, Vanessa , Owilli, Alex Olirus , Yang, Andrew X. , Finnegan, Amy, Westerhaus, Michael, Finnegan, Amy C.

Mayo Clinic

World Medical & Health Policy | February 24, 2022 | Volume: 14 | Issue: 1 | Pages: 54-73

10.1002/wmh3.503 Get It

AbstractAmidst the COVID‐19 pandemic and social uprisings demanding social and racial equity worldwide, there is an increasing demand for health justice training for health workers. However, there are scant evidence‐based assessments of the impact of such courses. Between 2010 and 2020, SocMed—a 501(c)3 non‐profit social justice organization—offered two distinct courses about health equity, the social determinants of health, and social medicine to health workers through the University of Minnesota in Minneapolis, Minnesota and Saint Mary Hospital Lacor in Gulu, Uganda. This study assesses the immediate impact of the SocMed curriculum on participants measured by a pre‐course and post‐course survey. In Minnesota, paired pre‐course and post‐course survey responses (mean n = 69; SD = 23) spanned years 2016–2019, while Uganda paired pre‐course and post‐course survey responses (mean n = 64; SD = 21) spanned years 2012–2013 and 2017–2019. Findings indicate that the course improved participants’ knowledge in all 24 of the topics in the Minnesota course and 42 of 44 topics in the Uganda course (significant at p < 0.05).
Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium
Quiroz, Yakeel T. , Solis, Michele M., Arbaje, Alicia I. , Arroyo‐Miranda, Mirna L, Cabrera, Laura Y. , Carrasquillo, Minerva M. , Corrada, María M. , Diminich, Erica D. , Dorsman, Karen A. , Gonzales, Mitzi M. , Gonzalez‐Seda, Ana L., Grinberg, Lea T. , Guerrero, Lourdes R. , Hill, Carl V. , Jiménez‐Velázquez, Ivonne Z. , Guerra, Jorge J. Llibre, Maestre, Gladys E. , Medina, Luis D. , Peñaloza, Claudia , Mavarez, Rosa V. Pirela, Pluim, Celina F., Raman, Rema , Rascovsky, Katya, Reyes, Yarissa, Rosselli, Mónica , Vila‐Castelar, Clara , Carrillo, María C. , Sexton, Claire E. , Carrasquillo, Minerva Maria, Sexton, Claire , Grinberg, Lea , Medina, Luis Daniel , Gonzales, Mitzi , Aranda, María , Carrasquillo, Minerva M. , Crivelli, Lucía , Gonzalez, Hector M , Lopera, Francisco Javier , O’Bryant, Sid E. , Mora-Pinzon, Maria C. , Pirela, Rosa V. , Rentz, Dorene M. , Tansey, Malú G. , Zuelsdorff, Megan L.

Mayo Clinic

Alzheimer's & Dementia | February 24, 2022 | Volume: 18 | Issue: 9 | Pages: 1677-1686

10.1002/alz.12589 | PMID 35199931 Get It

AbstractThe Alzheimer's Association hosted the second Latinos & Alzheimer's Symposium in May 2021. Due to the COVID‐19 pandemic, the meeting was held online over 2 days, with virtual presentations, discussions, mentoring sessions, and posters. The Latino population in the United States is projected to have the steepest increase in Alzheimer's disease (AD) in the next 40 years, compared to other ethnic groups. Latinos have increased risk for AD and other dementias, limited access to quality care, and are severely underrepresented in AD and dementia research and clinical trials. The symposium highlighted developments in AD research with Latino populations, including advances in AD biomarkers, and novel cognitive assessments for Spanish‐speaking populations, as well as the need to effectively recruit and retain Latinos in clinical research, and how best to deliver health‐care services and to aid caregivers of Latinos living with AD.
Pulmonary artery capacitance and pulmonary vascular resistance as prognostic indicators in acute pulmonary embolism
Quintero-Martinez, Juan Andres , Cordova-Madera, S N, Mogollon, Renzo , Garcia‐Arango, Mariana , Vlazny, Danielle T. , Villarraga, Hector R. , Quintero-Martinez, Juan A , Cordova-Madera, Sandra N., Mogollon, Renzo J, Garcia-Arango, Mariana, Wysokiński, Waldemar E. , Houghton, Damon E. , Casanegra, Ana I.

Mayo Clinic

European Heart Journal Open | February 24, 2022 | Volume: 2 | Issue: 2 | Pages: No page available

10.1093/ehjopen/oeac007 | PMID 35919120 Get It

AbstractAimsThe non-invasive calculation of right ventricular (RV) haemodynamics as pulmonary artery (PA) capacitance (PAC) and pulmonary vascular resistance (PVR) have proved to be feasible, easy to perform, and of high prognostic value. We, therefore, evaluated whether baseline PAC and PVR could predict clinical outcomes for patients with acute pulmonary embolism (PE).Methods and resultsWe prospectively followed 373 patients [mean (standard deviation) age, 64.1 (14.9) years; 58.4% were men, and 27.9% had cancer] who had acute PE and transthoracic echocardiography within 1 day of diagnosis from 1 March 2013 through 30 June 2020. Pulmonary artery capacitance was calculated as left ventricular stroke volume/(PA systolic pressure − PA diastolic pressure). Pulmonary vascular resistance was calculated as (tricuspid regurgitant velocity/RV outflow tract velocity time integral) × 10 + 0.16. These two variables were calculated retrospectively from the values obtained with transthoracic echocardiography. Pulmonary artery capacitance was acquired in 99 (27%) patients and PVR in 65 (17%) patients. Univariable and bivariable logistic regression analyses, and receiver operating characteristic curves were used to evaluate the ability of these haemodynamic measurements to predict mortality up to 6 months. After using bivariable models to adjust individually for age, cancer, and pulmonary hypertension. Pulmonary vascular resistance was associated with all-cause mortality at 3 months [area under the curve (AUC) 0.75, 95% confidence interval (CI) 0.61–0.86; P = 0.01], and 6 months (AUC 0.81; 95% CI 0.69–0.91; P≤ 0.03). Pulmonary artery capacitance was associated with all-cause mortality at 30 days (AUC 0.95; 95% CI 0.82–0.99; P &lt; 0.001) and 3 months (AUC 0.84; 95% CI 0.65–0.99; P = 0.003).ConclusionNon-invasive measurement of RV haemodynamics could provide prognostic information of patients with acute PE. Pulmonary artery capacitance and PVR are potentially important predictors of all-cause mortality in these patients and should be explored in future studies.
Durability of a simple repair method for commissural leaflet prolapse
Schaff, Hartzell V.

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | February 24, 2022 | Volume: 62 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezac141 | PMID 35278067 Get It

The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Tur, Carmen , Otero‐Romero, Susana , Amato, Maria Pia , Derfuss, Tobias , Pauli, Franziska Di , Abboud, Hesham , Achiron, Anat , Casanova, Jean‐Laurent , Clifford, David B. , Fonderico, Mattia , Gouider, Riadh , Hacohen, Yael , Kappos, Ludwig , Ladeira, Filipa , Louapre, Céline , Magyari, Melinda , Papeix, Caroline , Piehl, Fredrik , Ruíz-Camps, Isabel , Selmaj, Krzysztof , Simpson, Steve , Sıva, Aksel , Vaknin‐Dembinsky, Adi , Weinshenker, Brian G. , Winkelmann, Alexander, Rodas, María Isabel Zuluaga , Tintoré, Mar , Amato, Maria Pia , Derfuss, Tobias , Abboud, Hesham , Achiron, Anat , Dobson, Ruth , Filippi, Massimo , Fitzgerald, Kathryn C , Fonderico, Mattia , Hellwig, Kerstin , Hemmer, Bernhard , Ladeira, Filipa , Lebrun‐Frénay, Christine , Magyari, Melinda , Oreja-Guevara, Celia , Pandit, Lekha , Papeix, Caroline , Portaccio, Emilio , Simpson-Yap, Steve , Siva, Aksel , Sormani, Maria P , Vukusic, Sandra , Wiendl, Heinz , Tintoré, Mar , Weinshenker, Brian G , Casanova, Jean Laurent , Hacohen, Yael , Dubessy, Anne‐Laure , Iacobaeus, Ellen , Mycko, Marcin P. , Bellinvia, Angelo , Boyко, Alexey , Farez, Mauricio , Filippi, Massimo , Mehling, Matthias , Oreja‐Guevara, Celia , Pandit, Lekha , Sørensen, Per Soelberg , Sormani, Maria Pia , Trojano, María , Wiendl, Heinz , Stankoff, Bruno

Mayo Clinic

Multiple Sclerosis Journal | February 24, 2022 | Volume: 28 | Issue: 9 | Pages: 1424-1456

10.1177/13524585211069068 | PMID 35196927 Get It

Over the recent years, the treatment of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) has evolved very rapidly and a large number of disease-modifying treatments (DMTs) are now available. However, most DMTs are associated with adverse events, the most frequent of which being infections. Consideration of all DMT-associated risks facilitates development of risk mitigation strategies. An international focused workshop with expert-led discussions was sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and was held in April 2021 to review our current knowledge about the risk of infections associated with the use of DMTs for people with MS and NMOSD and corresponding risk mitigation strategies. The workshop addressed DMT-associated infections in specific populations, such as children and pregnant women with MS, or people with MS who have other comorbidities or live in regions with an exceptionally high infection burden. Finally, we reviewed the topic of DMT-associated infectious risks in the context of the current SARS-CoV-2 pandemic. Herein, we summarize available evidence and identify gaps in knowledge which justify further research.
Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial
Matteson, Eric L. , Distler, Jörg H. W. , Seibold, James R. , Mittoo, Shikha, Dellaripa, Paul F. , Aringer, Martin , Pope, Janet , Distler, Oliver , James, Alexandra, Schlenker‐Herceg, Rozsa, Stowasser, Susanne , Quaresma, Manuel , Flaherty, Kevin R. , Investigators, the INBUILD Trial, Distler, Jörg H W , Aringer, Martin , Pope, Janet , Distler, Oliver , Kelly, Clive Anthony , Hoffmann‐Vold, Anna‐Maria , James, Alexandra, Investigators, the INBUILD Trial

Mayo Clinic

Arthritis & Rheumatology | February 24, 2022 | Volume: 74 | Issue: 6 | Pages: 1039-1047

10.1002/art.42075 | PMID 35199968 Get It

ObjectiveTo analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a progressive phenotype.MethodsThe INBUILD trial enrolled patients with a fibrosing ILD other than idiopathic pulmonary fibrosis, with diffuse fibrosing lung disease of >10% extent on high‐resolution computed tomography, forced vital capacity percent predicted (FVC%) ≥45%, and diffusing capacity of the lungs for carbon monoxide percent predicted ≥30% to <80%. Patients fulfilled protocol‐defined criteria for progression of ILD within the 24 months before screening, despite management deemed appropriate in clinical practice. Subjects were randomized to receive nintedanib or placebo. We assessed the rate of decline in FVC (ml/year) and adverse events (AEs) over 52 weeks in the subgroup with autoimmune disease–related ILDs.ResultsAmong 170 patients with autoimmune disease–related ILDs, the rate of decline in FVC over 52 weeks was −75.9 ml/year with nintedanib versus −178.6 ml/year with placebo (difference 102.7 ml/year [95% confidence interval 23.2, 182.2]; nominal P = 0.012). No heterogeneity was detected in the effect of nintedanib versus placebo across subgroups based on ILD diagnosis (P = 0.91). The most frequent AE was diarrhea, reported in 63.4% and 27.3% of subjects in the nintedanib and placebo groups, respectively. AEs led to permanent discontinuation of trial drug in 17.1% and 10.2% of subjects in the nintedanib and placebo groups, respectively.ConclusionIn the INBUILD trial, nintedanib slowed the rate of decline in FVC in patients with progressive fibrosing autoimmune disease–related ILDs, with AEs that were manageable for most patients.
Outcomes following Distal Radioulnar Joint Arthroplasty in the Setting of Total or Partial Wrist Fusion
Amundsen, Asgeir , Rizzo, Marco , Berger, Richard A. , Moran, Steven L. , Berger, Richard, Frihagen, Frede

Mayo Clinic

Journal of Wrist Surgery | February 23, 2022 | Volume: 11 | Issue: 06 | Pages: 501-508

10.1055/s-0042-1743119 | PMID 36504533 Get It

Abstract Purpose To evaluate the functional outcome and complications following primary ulnar head or total distal radial ulnar joint (DRUJ) arthroplasty in patients who have a partial or total wrist fusion. Methods We conducted a retrospective review of 33 primary DRUJ implants in 31 patients who had a partial or total wrist fusion. Follow-up time averaged 67 months. There were 11 partial and 22 total wrist fusions with 22 ulnar head prosthesis and 11 total DRUJ implants. The mean age of the patients was 49 years. Eighty-one percent had previous surgeries with an average number of 4.6 previous wrist procedures. Pre- and postoperative pain levels were recorded. Mayo Wrist Scores were calculated. Grip strength, range of motion (ROM), and post-operative complications were noted. Results The pain scores improved in 67% of the patients. The Mayo Wrist Score improved significantly from a mean of 39 preoperatively to 51 postoperatively. The grip strength and pro-supination remained stable. The wrist ROM also remained stable in the patients with partial wrist fusions. During the follow-up period, 10 (30%) of the DRUJ implants were explanted, with a trend toward higher explantation rates in total wrist fusions with one in the partial fusion group and nine in the total wrist fusion group. Four of the explantations happened in the first postoperative year. Nineteen (61%) of the patients required a second surgery for a DRUJ implant-related complication; this rate was similar between the partial and total fusion groups. Conclusions DRUJ replacement resulted in improved pain scores and Mayo wrist scores in the majority of patients; however, the combination of primary DRUJ arthroplasty and total wrist fusion was associated with high complication rates. Surgeons should be aware of the high complication rate seen with DRUJ arthroplasty when combined with total wrist fusion.
EPPOCRATIS: Expedited Preoperative Point-of-Care Reduction of Fractures to Normalized Anatomy and Three-Dimensional Printing to Improve Surgical Outcomes
Sharaf, Basel, Kuruoglu, Doga, Cantwell, Sean R., Alexander, Amy E., Dickens, Hunter J., Morris, Jonathan M., Sharaf, Basel , Sharaf, Basel A , Kuruoglu, Doga, Cantwell, Sean R., Alexander, Amy E., Dickens, Hunter J., Morris, Jonathan M.

Mayo Clinic

Plastic & Reconstructive Surgery | February 23, 2022 | Volume: 149 | Issue: 3 | Pages: 695-699

10.1097/prs.0000000000008871 | PMID 35196689 Get It

Summary: Virtual surgical planning and three-dimensional printing have been invaluable tools in craniomaxillofacial surgery. From planning head and neck reconstruction to orthognathic surgery and secondary reconstruction of maxillofacial trauma, virtual surgical planning and three-dimensional printing allow the surgeon to rehearse the surgical plan and use patient-specific surgical guides for carrying out the plan accurately. However, the process of virtual surgical planning and three-dimensional printing requires time and coordination between the surgeon on one hand and the biomedical engineers and designers on the other hand. Outsourcing to third-party companies contributes to inefficiencies in this process. Advances in surgical planning software and three-dimensional printing technology have enabled the integration of virtual surgical planning and three-dimensional printing at the treating hospital, the point of care. This allows for expedited use of this process in semiurgent surgical cases and acute facial trauma cases by bringing the surgeon, radiologist, biomedical engineers, and designers to the point of care. In this article, the authors present the utility of EPPOCRATIS, expedited preoperative point of care reduction of fractures to normalized anatomy and three-dimensional printing to improve surgical outcomes, in the management of acute facial trauma.